Momentive Technologies and Stevanato Group collaborate on vials packaging

Momentive Technologies and Stevanato Group agreed to supply Momentive’s Pur Q fused quartz vials in Stevanato’s EZ-fill packaging format.

The Pur Q vials are ultra-high-purity fused quartz vials available for pharmaceutical packaging. The EZ-fill secondary packaging provides a fully integrated, ready-to-use option for aseptic fill-finish operations.

Combined, the move is expected to help biopharmaceutical companies improve the reliability and speed of drug development and production of medications via highly stable primary packaging and an efficient secondary packaging method.

Made from 99.995 percent pure silicon dioxide (SiO₂), the Pur Q fused quartz vials have an inert, nonreactive surface that virtually eliminates risk of interaction with packaged drug formulations.

“Due to the vials’ highly inert properties, biopharmaceutical companies will be able to confidently take the container out of the equation when assessing the viability of formulations, helping to accelerate the development of increasingly complex and sensitive biologic drug formulations,” said Robert Koch, global commercial director at Momentive Technologies.

The EZ-fill secondary packaging is designed to mitigate the risk of breakage, cosmetic issues and particulate generation during fill-finish operations. The packaging stores vials safely in a tray, or nest and tub configuration for efficient filling, while minimizing glass-to-glass contact.

Momentive Technologies, headquartered in Strongsville, Ohio, employs more than 700 workers and maintains seven manufacturing locations in the U.S., Germany, Japan and China. Formerly a division of Momentive Performance Materials, the business became a separate stand-alone entity in January.

Privately owned Stevanato Group, based in Piombino Dese, Italy, is a designer and producer of glass primary packaging for the pharmaceutical industry. In September, the company launched a Technology Excellence Center in Boston to support biopharma companies from early phase development through to commercialization, helping them overcome container-closure system hurdles.